(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…
Read full story Source: www.thestar.com.my Medical Disclaimer: This content is shared for informational and educational purposes only. It does not...
Research is still needed to determine whether cognitive training can reduce the risk of dementia Source: www.thehindu.com Medical Disclaimer: This...
Members of the House of Representatives are being urged to resolve a systemic "funding, education, and coordination" deficit facing the...
Our understanding of cancer has now changed: with advancements in imaging and pathology, it is now possible to tailor surgery...
Strengthening the hospital's commitment to making quality healthcare accessible to more Filipinos. Source: www.philstar.com Medical Disclaimer: This content is shared...
